Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
12,799
datasets available to search
ShareScore release 0.9.0
Dataset results
12,799 results for “Immunization”
MCT1 gene silencing enhances the immune effect of dendritic cells on cervical cancer cells
<p>Figur 1. xlsx, Results of ANOVA as presented in Figure 1.</p> <p>Figur 2. xlsx, Results of ANOVA as presented in Figure 2.</p> <p>Figur 3. xlsx, Results of ANOVA as presented in Figure 3.</p> <p>Figur 4. xlsx, Results of ANOVA as presented in Figure 4.</p> <p>Figur 5. xlsx, Results of ANOVA as presented in Figure 5.</p> <p>Figur 6. xlsx, Results of ANOVA as presented in Figure 6.</p> <p>Figur s1. xlsx, Results of ANOVA as presented in Figure s1.</p> <p>supplementary figure. docx, <strong>Figure S1</strong> Cube maps for the levels of expression for DC markers after sLA exposure and LPS challenge. DCs were first infected with Ad-shCtrl and Ad-shMCT1 adenoviruses for 24 h, then co-cultured with 50 mM sLA or PBS for 48 h, and finally stimulated with 1 ug/mL LPS for 24 h. Flow cytometry was used to detect the expression of CD1a (A), CD80 (B), CD83 (C), CD86 (D) and MHCII (E) in DCs.</p> <p>Table S1. docx, Statistics for Figure S1.</p>
Fig. 5 in Floro-pyrazolo[3,4-d]pyrimidine derivative as a novel plant activator induces two-pathway immune system
Fig. 5. The synthetic route of 1-methyl-4-substituted phenylamino pyrazolo [3,4-d] pyrimidine derivatives (P1).
Fig. 7 in Floro-pyrazolo[3,4-d]pyrimidine derivative as a novel plant activator induces two-pathway immune system
Fig. 7. The synthetic route of N-(1-methyl-1H-pyrazolo [3,4-d]pyrimidin-4-yl) substituted carboxamide derivatives (P3).
Fig. 6 in Floro-pyrazolo[3,4-d]pyrimidine derivative as a novel plant activator induces two-pathway immune system
Fig. 6. The synthetic route of 1-methyl-4-substituted ether pyrazolo [3,4-d] pyrimidine derivatives (P2).
Fig. 4 in Floro-pyrazolo[3,4-d]pyrimidine derivative as a novel plant activator induces two-pathway immune system
Fig. 4. Gene expression in Arabidopsis thaliana after treatment of chemicals. Bars (gray, PR1; black, PDF1.2) denote the mean ± STD of three independent biological replicates. (***P <0.01; **P <0.05; one-tailed t-test).
CCBB congenital CMV cohort immune cell subset RNA seq analysis
<p>CCBB congenital CMV cohort immune cell subset RNA seq analysis includes:</p> <p>1) metadata file with sample cell type and CMV infection status</p> <p>2) read counts for FAC-sorted cord blood immune cell subsets</p> <p>3) sample code for bulk RNA seq analysis and data visualization</p>
IA2030 Action Plans and Impact Acceleration Reports: Survey responses from 931 national and sub-national staff (Immunization Agenda 2030 Full Learning Cycle 2022)
<p># IA2030 Action Plans and Impact Acceleration Reports: Survey responses from 931 national and sub-national staff (Immunization Agenda 2030 Full Learning Cycle 2022)</p> <p>Note: This document includes markdown syntax to facilitate machine reading.</p> <p>## Table of Contents<br> - Abstract<br> - Research Audience<br> - Credits<br> - Recommended Citation<br> - File List<br> - Related Data Sets<br> - Background<br> - Data Set Structure and Contents<br> - Data Cleaning, Data Privacy, and Anonymization<br> - Ethical Considerations<br> - Survey Implementation<br> - Survey Questionnaire Items<br> - Data Availability and Accessibility<br> - Copyright and License<br> - References</p> <p>## Abstract</p> <p>The Immunization Agenda 2030 (IA2030) has been endorsed at the World Health Assembly as the world’s strategy for immunization.</p> <p>The Movement for IA2030 is a voluntary collective of immunization practitioners, principally from low- and middle-income countries, who have pledged to support each other to accelerate local action in support of this global immunization strategy.</p> <p>This data set offers insights into how to understand national and sub-national challenges facing immunization programmes and what strategies show promise for addressing these challenges over time. It contains:<br> - raw, anonymized data in Excel CSV format. Copies of the three survey questionnaires are available for download in the Files section (below).<br> - responses to one, two, or three surveys from 931 national and subnational immunization practitioners participating in the Movement for Immunization Agenda (IA) 2030:</p> <p>Survey 1: IA2030 Action Plan Survey: a 77-item questionnaire, fielded in May 2022, which asked respondents to identify a key challenge relevant to their immunization programme, root cause of the challenge, three corrective actions, and what they knew about vaccination coverage in their zone of intervention.</p> <p>Survey 2: IA2030 Impact Acceleration Report Survey (2022): a 27-item questionnaire, fielded in June 2022, which asked respondents to report progress on implementation of their IA2030 Action Plan, including progress on vaccination coverage indicators.</p> <p>Survey 3: IA2030 Impact Acceleration Report Survey (2023): a 60-item questionnaire, fielded in June 2023, which asked respondents to report progress on implementation of their IA2030 Action Plan, including progress on vaccination coverage indicators.</p> <p>## Research Audience</p> <p>Education and global health researchers with interest in human resources for health (HRH) and the characteristics, priority challenges, and experiences of national and sub-national immunization staff participating in the Movement for Immunization Agenda (IA) 2030.</p> <p>## Credits</p> <p>### Author</p> <p>The Geneva Learning Foundation (TGLF)<br> 18 Avenue Louis Casaï <br> CH1209 Geneva, Switzerland<br> research@learning.foundation</p> <p>Principal Investigator and Corresponding Author<br> Reda Sadki, TGLF<br> reda@learning.foundation</p> <p>Project Partners<br> - Biostat Global Consulting (BGC)<br> - Bridges to Development<br> - Centre for Change & Complexity in Learning (C3L)</p> <p>Partner Roles and Responsibilities<br> - Design: TGLF<br> - Implementation (sample collection): TGLF<br> - Processing: TGLF, C3L<br> - Anonymization: BGC<br> - Submission: TGLF<br> - Maintenance of learning analytics database where data are stored: C3L</p> <p>Funding<br> Wellcome Trust, Bill & Melinda Gates Foundation (BMGF)</p> <p>## Recommended Citation</p> <p>Action Plans and Impact Acceleration Reports: Responses from 931 national and sub-national staff (Immunization Agenda 2030 Full Learning Cycle). The Geneva Learning Foundation, 2023. (Version 1.0) [Data Set]. The Geneval Learning Foundation. https://doi.org/10.5281/zenodo.8298773</p> <p>## File List</p> <p>2023-09.IA2030_Action_Plans_and_Impact_Acceleration_Reports.README.md (this document)</p> <p>2022-05.IA2030_Action_Plan_Survey.docx: List of items included in the Action Plan Survey</p> <p>2022-06.IA2030_Impact_Acceleration_Report_Survey.docx: List of items included in the Impact Acceleration Report Survey questionnaire administered in June 2022.</p> <p>2023-06.IA2030_Impact_Acceleration_Report_Survey.docx: List of additional items included in the Impact Acceleration Survey administered in June 2023 (the complete survey questionnaire also included all items included in the June 2022 Impact Acceleration Report Survey questionnaire).</p> <p>2023-09.IA2030_Action_Plans_and_Impact_Acceleration_Reports_Survey_Dataset.csv: Anonymized Action Plans and Acceleration Reports Survey Dataset. Version 1: Geneva Learning Foundation (937 observations, 173 variables).</p> <p>## Related Data Sets</p> <p>The 2023-09.IA2030_Action_Plans_and_Impact Acceleration_Reports_Survey_Dataset.csv is a subset of data collected by The Geneva Learning Foundation (TGLF) during the first IA2030 Full Learning Cycle (FLC) during May 2022, June 2022, and June 2023. The complete IA 2030 Action Plans and Impact Acceleration Reports Survey data set is more comprehensive and includes information about respondent and programme characteristics as well as responses to open-text questions. </p> <p>Researchers who would like to analyze the full set of unredacted responses are invited to contact the Geneva Learning Foundation to inquire about a data sharing agreement that would stipulate conditions of access (insights@learning.foundation).</p> <p>The Geneva Learning Foundation, 2023. Value Creation Stories (VCS) weekly feedback survey, 2022 Full Learning Cycle (FLC) of the Movement for Immunization Agenda 2030 (IA2030) (Version 1.0). [Data Set]. The Geneva Learning Foundation. https://doi.org/10.5281/zenodo.7763922 </p> <p>The Geneva Learning Foundation, 2023. Full Learning Cycle (2022) Application for national and sub-national immunization staff to identify challenges and join the Movement for Immunization Agenda (IA 2030) (Version 1.0) [Data Set]. The Geneval Learning Foundation. https://doi.org/10.5281/zenodo.8199552</p> <p>Additional data sets for the first Full Learning Cycle (FLC) of the Movement for Immunization Agenda 2030 (IA2030) are available from TGLF’s Insights Unit (insights@learning.foundation).</p> <p>## Background</p> <p>The Immunization Agenda 2030 (IA2030), the global immunization strategy for 2021-2030, set ambitious targets for global immunization coverage and other key indicators (World Health Organization [WHO], 2020).</p> <p>In response to the WHO Director-General’s call for a social movement to ensure immunization remains a priority for global and regional health agendas and promote broad societal support for immunization (WHO, 2020), TGLF, working with its global community of over 35,000 alumni, developed a learning programme intended to contribute to a “Movement for Immunization Agenda 2030.” As part of their participation in the programme, IA2030 participants developed a locally tailored action plan designed to address a key challenge relevant to their immunization programme. A project kick-off phase, the “Impact Accelerator Launch Pad”, supported participants during their initial implementation stages, to create momentum for sustained action. One month after initiation of their Action Plan(s), participants were invited to complete an Impact Acceleration survey questionnaire to assess progress towards their goals. One year later, programme participants were invited to complete a second Impact Acceleration questionnaire to assess continued progress towards their goal.</p> <p>This data set includes participants’ responses to one or more questionnaires documenting their IA2030 experience:<br> - Survey 1: IA2030 Action Plan Survey: a 77-item questionnaire, fielded in May 2022, which asked respondents to identify a key challenge relevant to their immunization programme, root cause of the challenge, three corrective actions, and what they knew about vaccination coverage in their zone of intervention.<br> - Survey 2: IA2030 Impact Acceleration Report Survey (2022): a 27-item questionnaire, fielded in June 2022, which asked respondents to report progress on implementation of their IA2030 Action Plan, including progress on vaccination coverage indicators.<br> - Survey 3: IA2030 Impact Acceleration Report Survey (2023): a 60-item questionnaire, fielded in June 2023, which asked respondents to report progress on implementation of their IA2030 Action Plan, including progress on vaccination coverage indicators.</p> <p>## Data Set Structure and Contents</p> <p>The data set has 937 observations and 173 variables. Contents include the following:<br> - 937 responses (532 English; 405 French) to the Action Plan Survey. Six individuals submitted two distinct Action Plans.<br> - 538 responses (278 English; 260 French) to the 2022 Impact Acceleration Report Survey<br> - 236 responses (126 English; 110 French) to the 2023 Impact Acceleration Report Survey<br> - Column A describes the type of data included in each row of the data file<br> - The first two rows of the data set hold the question text in English and in French<br> - Column B contains a unique identifier for each respondent. The ID is a simple string starting with a number to indicate a unique person and then a dash, and then a 1 or a 2 to indicate whether it is their first or second entry for the 2022 Impact Acceleration Report Survey. <br> - Columns D-F indicate the language each respondent used for each of the three questionnaires (EN = English; FR = French)<br> - The columns whose names start with I1 were collected as part of the Action Plan Survey, I2 as part of the 2022 Impact Acceleration Report Survey, and I3 as part of the 2023 Impact Acceleration Report Survey. The columns appear in left-to-right order in which the original surveys were administered.</p> <p>## Data Cleaning, Data Privacy, and Anonymization</p> <p>Duplicate surveys submitted by the same individual were removed from the data set. When a respondent submitted multiple versions of the Action Plan or 2023 Impact Acceleration Report Survey, the submission with the most complete responses was retained. Six persons submitted two distinct records for the 2022 Impact Acceleration Report Survey. In those cases, both responses appear in the dataset, paired with that person’s single retained entry for the Action Plan and their single retained entry for the 2023 Impact Acceleration Report Survey (where applicable).</p> <p>The data file shared on this site is intentionally incomplete. Columns containing holding personally identifying information (e.g., respondent email address, date of birth, WhatsApp number, organization name, country) and columns potentially holding personally identifying information (e.g., responses to items such as “summarize your challenge,” “tell us about your stakeholders”) have been replaced with the following phrases:</p> <p>- “Removed to protect personally identifying information” (English questionnaires)<br> - “Supprimé pour protéger les informations personnelles” (French questionnaires)</p> <p>## Ethical Considerations </p> <p>Ethical clearance for each of the three surveys was granted by TGLF prior to its administration. Privacy was safeguarded by data management complying with the [General Data Protection Regulation](https://gdpr-info.eu/). All participants were informed that participation was voluntary and were assured their data would be confidential. Participants provided consent prior to completing each survey. Respondents did not receive any incentive for participating in any of the surveys.</p> <p>All information collected for the three surveys was secured with multiple levels of encryption and access controls to guarantee participant confidentiality, per [Typeform policy](https://www.typeform.com/help/a/security-at-typeform-360029259552/)).</p> <p>## Survey Implementation</p> <p>For each of the three surveys, IA2030 participants received an email message inviting them to complete a questionnaire. Respondents accessed the questionnaire by clicking a link contained in the email.</p> <p>All surveys were hosted on the Typeform server and followed the same methods for protecting respondent privacy (details provided in Ethical Considerations section, above). Respondents were given the choice of completing each questionnaire in either English or French.</p> <p>All survey questionnaires included a mixture of multiple-choice and open-text items. Overviews of the contents of each survey are provided in the next three subsections. Copies of the survey instruments are available for download in the Files section (below).</p> <p>## Survey Questionnaire Items</p> <p>### IA 2030 Action Plan Survey Items</p> <p>- To start your IA2030 Action Plan, describe one challenge you face in your immunization work. We suggest you focus on your most difficult and important challenge. Focus on only one problem where you can take action. Be specific about your situation, not generalities. Help others understand why it matters. Explain your situation. What is the root cause of your challenge? What will be different if you overcome this challenge?<br> - Summarize your challenge and what you want to do about it.<br> - Is your challenge too broad, general, or vague, like “coverage is too low” or “there are unvaccinated children”? Can you take action at your level to tackle this challenge?<br> - Immunization Agenda 2030 is organized into seven Strategic Priorities (SP). Review the list carefully to select the Strategic Priority that best fits your challenge. IA2030 Strategic Priorities are organized into 47 Key Focus Areas (KFAs). Review the list carefully to select the item that best fits your challenge.<br> - Is your challenge related to any of these?<br> - To tackle your challenge, define the goal of your IA2030 Action Plan.<br> - Why is this goal important? Answer the question, “If I achieve my goal, what will be different?” What does success look like?<br> - Have you started to take action toward this goal?<br> - Summarize what you have already done toward this goal. Who did what, when and how? How did it turn out? Do you have any concrete results to date? What are the lessons or surprises so far?<br> - Tell us about your stakeholders. Who will you need to work with to achieve your goal? What type of support will you need from the communities you serve? How should your organization, supervisor, and partners support you? What are the likely barriers to securing their support and commitment? What are you going to do if a stakeholder does not provide the support you need? Could the support of IA2030 Movement colleagues be helpful to you and, if so, how?<br> - Do you need additional funding to achieve your goal?<br> - How much time do you need to achieve your goal? (Less than one month, 1-3 months. 4-6 months, 7-12 months, 13-18 months, 19-24 month, more than 24 months)<br> - Tell us more about resources and timeline. Provide a rough initial estimate of the time and budget required for your Action Plan. If this is premature, indicate what you need to know to be able to determine time and budget required.<br> - What resources (time, people, money) will you need to achieve your goal? How are you going to secure these resources? Summarize the steps to secure resources.<br> - Now, we would like you to identify three different, specific actions to achieve the goal of your IA2030 Action Plan: Action 1. What do you want to do? Have you done this before? Who will carry out this action? How much time do you need to finish this action? How innovative is this action? Tell us more about this action?<br> - Explain why this action matters. How will this action help you achieve your goal? What needs to happen and when? What are the steps to finish this action? Who will carry out this action? How will you know when you have finished your action? How will you know if your action is successful?<br> - What else needs to happen to achieve your goal?<br> - What other actions need to be taken? When do they need to happen? Who will carry them out? How will these actions help to achieve your goal? What is your role in them? What control do you have over these actions?<br> - Do you wish to share experience to help you with your IA2030 Action Plan and to help others?<br> - What is the name of your organizational unit or area of intervention?<br> - What is the main type of environment in: [your zone of intervention]?<br> - Do you know the size of the vaccination target population in: [your zone of intervention]?<br> - What is the size of the population in: [your zone of intervention]?<br> - Do you know the number of outreach immunization sessions that were planned and then actually carried out last year:<br> - What was the number of planned outreach immunization sessions held last year in: [your zone of intervention]?<br> - What was the number of outreach immunization sessions that were actually carried out last year in: [your zone of intervention]?<br> - Do you know the Antenatal Care (ANC) Coverage in: [your zone of intervention]?<br> - What is the Antenatal Care (ANC) Coverage in: [your zone of intervention]?<br> - Do you know the current Penta 1 coverage in: [your zone of intervention]?<br> - What is the current Penta 1 coverage in: [your zone of intervention]?<br> - Do you know the current Penta 3 coverage in: [your zone of intervention]?<br> - What is the current Penta 3 coverage in: [your zone of intervention]?<br> - Do you know the MCV1 immunization coverage in: [your zone of intervention]?<br> - What is the MCV1 immunization coverage in: [your zone of intervention]?<br> - Do you know the MCV2 immunization coverage in: [your zone of intervention]?<br> - What is the MCV2 immunization coverage in: [your zone of intervention]?<br> - Do you know the vaccination coverage for the first dose of COVID-19 vaccine in: [your zone of intervention]?<br> - What is the vaccination coverage for the first dose of COVID-19 vaccine in your area?<br> - You have now prepared your IA2030 Action Plan. Are you ready to take action? If your Action Plan is accepted, you will be invited to join the 2nd IA2030 Impact Accelerator Launch Pad to work with others during four weeks to start implementing your Action Plan.<br> - What will you seek to achieve in the FOUR WEEKS of the Launch Pad?<br> - What is the MOST IMPORTANT ACTION that you will carry out in the first 7 days of joining the Launch Pad?</p> <p>### IA2030 Impact Acceleration Report Survey Items (2022)</p> <p>- Has there been a CHANGE or PROGRESS since your last Acceleration Report? Tell us what has happened. -What has changed since your last Acceleration Report?<br> - What is the implementation status of your action plan?<br> - (If applicable) Please tell us why you have not yet started to implement your IA2030 action plan. What are the barriers or obstacles that have prevented you from starting implementation? What support do you need that will help you overcome these barriers? What will you do now to start implementing?<br> - Tell us more about the implementation status of your action plan. What actions did you take and what changed as a result of your actions? What are the results? What were the challenges and how did you address them? What strategies or solutions were critical to implementation? Who or what helped you? What lessons did you learn? Was there anything that surprised you? Is there anything else you would like us to know?<br> - Is your action plan integrated with the broader EPI programme?<br> - Has participation in your Scholar Country Team’s activities been USEFUL to you?<br> - Have you interacted personally with other members of the IA2030 Movement since your last Acceleration Report?? (If yes) What was the main reason for this interaction?<br> - How many Movement members have you personally interacted with since your last Acceleration Report?<br> - Name up to three Movement members that you have personally interacted with since your last Acceleration Report.<br> - Do you have something you would like to share about implementation of your IA2030 action plan? (If yes) Please tell us what happened and how it turned out. Why does this matter? How did you identify it? What have you done to learn more about it? What strategies or solutions have you tried or would you consider? Who or what can help you? What lessons have you learned so far? Was there anything that surprised you? Anything else that we need to know?<br> - Did you participate in the IA2030 Impact Accelerator Launch Pad from 23 May - 17 June 2022?<br> - Has your participation in the Accelerator helped you progress toward implementation of your IA2030 action plan? Tell us how the Accelerator has helped (or not) you progress toward implementation of your IA2030 action plan.<br> - What was the most valuable aspect of the Accelerator for you?<br> - Would you participate in the next IA2030 Impact Accelerator Launch Pad?<br> - Any other comments or feedback?</p> <p>### IA2030 Impact Acceleration Report Survey Items (2023)</p> <p>*Same questions as for Accelerator Report 2022, with the addition of the<br> following:*</p> <p>- How many HOURS PER WEEK on the average did you EXPECT TO SPEND to implement your plan?<br> - How many HOURS PER WEEK on the average did you ACTUALLY DEDICATE to implement your plan?<br> - What percentage of your work time have you spent on implementation of this action plan?<br> - Did someone provide funding towards the implementation of your action plan? (specify)<br> - Estimate the total budget in U.S. dollars (USD or US$) you need to implement your action plan. You will then be asked to justify this budget.<br> - If you have not yet developed a budget for your action plan, a rough estimate will suffice. Enter this amount in U.S. dollars.<br> - Do you need additional financial resources to successfully implement your action plan?<br> - Of this total budget US$ ,how much are you currently short, in U.S. dollars?<br> - Do you know where to get this additional funding for your action plan?<br> - Justify your estimate of this budget (US$ ) and the need for additional resources (if any).<br> - Summarize what these resources would be used for. Without these resources, what will happen?<br> - If your action plan is successful, how many more people will be vaccinated?<br> - If your action plan is successful, what will be different for the target population?<br> - In the last year, has there been a significant change in vaccination coverage indicators?<br> - This change is the result of my involvement in the IA2030 Movement (range: 1=Strongly disagree to 6=Strongly agree)<br> - To what do you primarily attribute this change?<br> - Explain why you primarily attribute this change to [factor]<br> - Without [factor] what would have been different? Why? How did your involvement in the IA2030 Movement contribute to this change?</p> <p>## Data Availability and Accessibility</p> <p>This data set is being made available through Zenodo, an open access repository. There are no restrictions on access to open data except those stated in the copyright and license. Researchers who would like to analyze the full set of unredacted responses are invited to contact the Geneva Learning Foundation to inquire about a data sharing agreement that would stipulate conditions of access (<insights@learning.foundation>).</p> <p>## Copyright and License</p> <p>© The Geneva Learning Foundation 2023.</p> <p>This data set and all associated files are licensed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0)</p> <p>Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International; https://creativecommons.org/licenses/by-nc-sa/4.0/.</p> <p>Under the terms of this license, you may copy, redistribute and adapt the data set for non-commercial purposes, provided the work is appropriately cited, as indicated above. In any use of this data set, there should be no suggestion that the Foundation endorses any specific organization, products, or services. Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.</p> <p>### General disclaimers</p> <p>The designations employed and the presentation of the data set do not imply the expression of any opinion whatsoever on the part of the Foundation concerning the legal status of any country, territory, city or area or of its authorities. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the Foundation in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of all reasonable precautions have been taken by the Foundation to verify the information contained in this data set. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for interpretation and use of the material lies with the reader. In no event shall the Foundation be liable for damages arising from its use.</p> <p>The data set contains individual views and does not necessarily represent the decisions or the policies of the Foundation.</p> <p>Version 1.0 (September 2023).</p> <p>## References</p> <p>Asiwome Kosi Abiwu, P.H., and Jones, I. (2022). IA2030 Case study 5. Paul Hilarius Asiwome Kosi Abiwu. View from the frontline: building stronger systems (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo7004284.</p> <p>Ateke, N.A., and Jones, I. (2022). IA2030 Case study 4. Njoh Andreas Ateke. View from the frontline: working with communities to strengthen immunization programmes (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo7004263.</p> <p>Ekwam, D.K., and Jones, I. (2022). IA2030 Case study 13. Pharm. Daniel Kwesi Ekwam. Covering all the bases (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo7010227.</p> <p>Faye, W., Jones, I., Mbuh, C., and Sadki, R. (2023). IA2030 Case study 18. Wasnam Faye. Vaccine angels - Give us the opportunity and we can perform miracles. (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo7785244.</p> <p>Faye, W., Jones, I., Mbuh, C., and Sadki, R. (2023). IA2030 Étude de cas 18. Wasnam Faye. Les anges de la vaccination: « Donnez-nous l’occasion et nous ferons des miracles. » (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7849329.</p> <p>Ferrah Conteh, Z., and Jones, I. (2022). IA2030 Case study 6. Zainab Ferrah Conteh. View from the frontline: Strenghtening the immunization programme backbone (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010079.</p> <p>Iwot, N., and Jones, I. (2022). IA2030 Case study 14. Ndaeyo Iwot. Building the capacities of communities (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010211.</p> <p>Jones, I., Mbuh, C., and Sadki, R. (2023). Listening and Learning at Teach to Reach 7 (IA2030 Listening and Learning Report 4) (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7766585.</p> <p>Jones, I., Mbuh, C., and Sadki, R. (2023). Teach to Reach 7: Partager pour apprendre (Rapport IA2030 «Écouter pour apprendre n° 4) (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7851783.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). IA2030 Case study 1. A digital health platform for immunization and primary health care (PHC) engagement (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.6982953.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). IA2030 Case study 1. A digital health platform for immunization and primary health care (PHC) engagement (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.6982953.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). IA2030 Case Study 10. Development of zero dose situational analyses and action plans (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010177.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). IA2030 Case study 2. Squaring the circle: safeguarding existing immunization programmes and primary healthcare during COVID-19 vaccination (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7004191.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). IA2030 Case Study 8. Practitioners’ perceptions of key immunization challenges (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7005241.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). IA2030 Listening and learning report 1. Working groups consultative engagement through a peer learning platform (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010140.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). IA2030 Movement Year 1 report. Consultative engagement through a digitally enabled peer learning platform (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7119648.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). IA2030. Listening and learning report 3. Everyone, everywhere: digital peer learning to leave no one behind (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010209.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). Mouvement pour la vaccination à l’horizon 2030. Rapport Écouter pour apprendre n° 3. Partout, pour tous: l’apprentissage numérique par les pairs pour que personne ne reste sur le côté (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7142102.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., Kovanovic, V., et al. (2022). IA2030 Rapport «Écouter pour apprendre» n° 2. Notre engagement pour la vaccination #VaccinesWork (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7254160.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., Kovanovic, V., et al. (2022). IA2030.Listening and learning report 2. It takes people to make #VaccinesWork (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010196.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Yagnik, A., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., et al. (2022). IA2030 Case Study 9. Understanding and responding to zero-dose challenges (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010171.</p> <p>Jones, I., Watkins, K.E., Sadki, R., Brooks, A., Gasse, F., Yagnik, A., Mbuh, C., Zha, M., Steed, I., Sequeira, J., et al. (2022). IA2030 Case Study 7. Motivation, learning culture and programme performance (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7004304.</p> <p>Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V.(2022). IA2030 Year 1 report. Consultative engagement through a digitally enabled peer learning platform (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7119648.</p> <p>Jones, I., Watkins, K.E., Sadki, R., Brooks, A., Gasse, F., Yagnik, A., Mbuh, C., Zha, M., Steed, I., Sequeira, J., et al. (2022). IA2030 Case Study 7. Motivation, learning culture and programme performance (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7004304.</p> <p>Kaboré, B., and Jones, I. (2022). IA2030 Case study 12. Boureima Kaboré. Delivering services in conflict-affected areas (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010188.</p> <p>Kuotong Nongho, R., and Jones, I. (2022). IA2030 Case study 3. Kuotong Nongho Rogers. View from the frontline: microplanning for equity (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7004235.</p> <p>Mbuh, C., Gasse, F., Jones, I., Sadki, R., Brooks, A., Zha, M., Steed, I., Sequeira, J., Churchill, S., and Kovanovic, V. (2022). IA2030 Case study 16. Continuum from knowledge to performance (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7014392.</p> <p>Monga, F., Jones, I., Mbuh, C., and Sadki, R. (2023). IA2030 Case study 19. Franck Monga. Building a movement for IA2030 in the Democratic Republic of Congo (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7794726.</p> <p>Monga, F., Jones, I., Mbuh, C., and Sadki, R. (2023). IA2030 Étude de cas 19. Franck Monga. Construire un Mouvement pour la vaccination en République Démocratique du Congo (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7851476.</p> <p>Monzón, M.F., Jones, I., Mbuh, C., and Sadki, R. (2023). IA2030 Case study 17. María Fernanda Monzón. Speaking up for frontline staff (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7785024.</p> <p>Monzón, M.F., Jones, I., Mbuh, C., and Sadki, R. (2023). IA2030 Étude de cas 17. María Fernanda Monzón. Prendre la parole au nom des personnels de première ligne (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7848308.</p> <p>Oketch, P., and Jones, I. (2022). IA2030 Case study 15. Penina Oketch. Planning, people and performance (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010242.</p> <p>Sadki, R., Mbuh, C., Szylovec, A.P., and Brooks, A. (2023). Value creation stories anonymized open data set (Immunization Agenda 2030 Full Learning Cycle, 7 March - 20 June 2022). https://doi.org/10.5281/zenodo.7763922.</p> <p>Sadki, R. Mbuh, C., Zha, M., Gasse, F., Brooks, A. The Geneva Learning Foundation, 2023. Full Learning Cycle (2022) Application for national and sub-national immunization staff to identify challenges and join the Movement for Immunization Agenda (IA 2030) (Version 1.0) [Data Set]. The Geneval Learning Foundation.https://doi.org/10.5281/zenodo.8199552</p> <p>Umbelino-Walker, I., Szylovec, A.P., Brooks, A., Sadki, R., Mbuh, C., Jones, I., Monglo, A., Dakan, B.A. (2023). Towards a sustainable model for a digital learning network in support of the Immunization Agenda 2030 -- a mixed methods study with a transdisciplinary component. Manuscript under review.</p> <p>WHO (2020). Immunization Agenda 2030: A Global Strategy to Leave No One Behind [Internet]. Available from: https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030. </p> <p>Yagnik, A., Jones, I., Sadki, R., Brooks, A., Gasse, F., Mbuh, C., Zha, M., Steed, I., Sequeira, J., Churchill, S., et al. (2022). IA2030 Case Study 11. Gender barriers to immunization (The Geneva Learning Foundation) https://doi.org/10.5281/zenodo.7010184.</p>
MAPK p38 and NFkB activity dynamics in macrophages upon innate immune stimulation
<p>Dataset (.mat structure) containing single cell p38 and NFkB activity dynamics in macrophages (iMPDMs) upon innate immune stimulation (LPS, TNF, P3C4, CpG) (1 h baseline + app 8 h stimulation).</p> <p>Two biological replicates per stimulation condition are included. 6 doses per stimulus are included.</p> <p>Signaling dynamics are quantified using live cell microscopy followed by automated image analysis by MACKtrack.</p> <p>Datasets include dynamic features ('metrics'), MACKtrack quantification outputs ('measure'), info on experimental (esp. dose), tracking, and quantification parameters, and filtering outcomes ('info').</p>
The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity - Merged datasets
<p><strong>Dataset from article</strong> : The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity</p> <p>10X Single-cell RNA-sequencing dataset (5/5).<br> Merged datasets: Run 1 cDNA 1 + Run 1 cDNA 2 + Run 2 cDNA 1 + Run 2 cDNA 2</p> <p>This repository contains results and necessary files for reproducing the analyses in Miallot et al. (2023). The instructions for reproducing the analysis are given in github (https://github.com/CIML-bioinformatic/PNlab_Sarcoma) and extra files are available in GEO/SRA (GSE221164).</p>
The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity - Run 1 cDNA 1
<p><strong>Dataset from article</strong> : The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity</p> <p>10X Single-cell RNA-sequencing dataset (1/5).<br> RUN 1(/2), cDNA 1(/2).</p> <p>This repository contains results and necessary files for reproducing the analyses in Miallot et al. (2023). The instructions for reproducing the analysis are given in github (https://github.com/CIML-bioinformatic/PNlab_Sarcoma) and extra files are available in GEO/SRA (GSE221164).</p>
The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity - Run 2 cDNA 2
<p><strong>Dataset from article</strong> : The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity</p> <p>10X Single-cell RNA-sequencing dataset (4/5).<br> RUN 2(/2), cDNA 2(/2).</p> <p>This repository contains results and necessary files for reproducing the analyses in Miallot et al. (2023). The instructions for reproducing the analysis are given in github (https://github.com/CIML-bioinformatic/PNlab_Sarcoma) and extra files are available in GEO/SRA (GSE221164).</p>
The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity - Run 2 cDNA 1
<p><strong>Dataset from article</strong> : The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity</p> <p>10X Single-cell RNA-sequencing dataset (3/5).<br> RUN 2(/2), cDNA 1(/2).</p> <p>This repository contains results and necessary files for reproducing the analyses in Miallot et al. (2023). The instructions for reproducing the analysis are given in github (https://github.com/CIML-bioinformatic/PNlab_Sarcoma) and extra files are available in GEO/SRA (GSE221164).</p>
The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity - Run 1 cDNA 2
<p><strong>Dataset from article</strong> : The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity</p> <p>10X Single-cell RNA-sequencing dataset (2/5).<br> RUN 1(/2), cDNA 2(/2).</p> <p>This repository contains results and necessary files for reproducing the analyses in Miallot et al. (2023). The instructions for reproducing the analysis are given in github (https://github.com/CIML-bioinformatic/PNlab_Sarcoma) and extra files are available in GEO/SRA (GSE221164).</p>
Spatiotemporal Profiling Unveiling the Cellular Organization Patterns and Local Protumoral Immune Microenvironment Remodeling in Early Lung Adenocarcinoma Progression
<p>Spatial cellular organization patterns (COPs) in tumor microenvironment influence the tumor progression and therapeutic response, however, little is known about the cellular composition and functional potential of these multicellular structures during lung adenocarcinoma progression. Here, we integrate spatial transcriptomics with single cell RNA sequencing to characterize the local tumor and immunological landscape of samples from 8 patients with lung adenocarcinoma at different pathological stages. We identified ten COPs that show distinct associations with local immune states and clinical outcomes, including survival and therapy response. The local infiltration levels of regulatory and dysfunctional immune cells are increased with pathological progression. Cell-to-cell interactions between malignant cells and tumor microenvironment (TME) cells were involved in protumor immune state remodeling. Finally, we detected a group of malignant cells that were specifically located at the tumor boundary, representing a more aggressive state, were involved in the invasion of invasive adenocarcinoma (IAC). Altogether, these results can improve our understanding of the local microenvironment characteristics that underlie LUAD progression and may facilitate the identification of drug targets to prevent invasive progression and biomarkers for diagnosis.</p><p>If you're going to use this dataset, please cite 'Haojie Chen et al. 2023. Protumoral Immune Microenvironment Remodeling in Early Lung Adenocarcinoma Progression. bioRxiv. https://doi.org/10.1101/2023.10.29.564580'</p>
Assessment of the Humoral Immune Response to the SARS-CoV-2 Spike Protein Receptor Binding Motif
<p><strong>Figure S1.</strong> Purification of human antibodies against the RBM region of the SARS-CoV-2 spike protein using a recombinant RBM Sepharose 4B affinity column (3 x 1 cm, inner diameter) (A) and SDS-PAGE (10%) analysis of the eluate (1) alongside a standard low molecular weight marker (Sigma Chemical Co, Saint Louis, Mo, U.S.A.) stained with Coomassie Blue. <strong>Table S1</strong>: Microscale thermophoresis (MST) traces of anti-RBM antibodies binding to different concentrations of S1WT (red) and S2WT (green) peptides by MST. Relative fluorescence (RF) between the bound and unbound state was determined over a time of 21s with 20s MST-on time for evaluation. The blue bar indicates the ΔRF before the temperature gradient was applied, whereas the red bar shows the ΔRF during the thermophoresis. For interaction experi ments, the amount of NT.647-labeled antibodies was kept constant, while the concentration of unlabeled peptides varied from 0.5 µg/mL–0.12 ng/mL. The assay was performed in PBS containing 0.05% Tween 20 and after a short incubation period, the samples were analyzed in standard glass MST NT.115 capillaries. <strong>Table S2:</strong> One-dose regime AstraZeneca-Oxford vaccinated serum information. <strong>Table S3</strong>: Heterologous booster dose vaccinated serum information.</p>
Synchronized Immunization NotifiCations
ClinicalTrials.gov study NCT02710318. IPD Sharing: NO. Countries: 1. Publications: 1.
Maternal Immunization To Prevent Infant Otitis Media
ClinicalTrials.gov study NCT00617682. IPD Sharing: Not stated. Countries: 1. Publications: 3.
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
ClinicalTrials.gov study NCT07330596. IPD Sharing: NO. Countries: 1. Publications: 9.
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
ClinicalTrials.gov study NCT01386437. IPD Sharing: Not stated. Countries: 1. Publications: 6.
The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure
ClinicalTrials.gov study NCT02967419. IPD Sharing: Not stated. Countries: 1. Publications: 18.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.